Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director | February 18, 2026 | February 20, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | PRINCIPAL FINANCIAL OFFICER | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 247,047 |
Reported balance
After 2026-02-18 transaction · row 1
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 48,828 · Balance 247,047 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.
SANGAMO THERAPEUTICS, INC
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 660,042 |
Reported balance
After 2026-01-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-22 · Tax withholding · Disposed 36,676 · Balance 660,042 F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 2, 2021 02:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,863 | $11.19 | $20,846.97 |
DisclosureSEC source: 0001209191-21-015525 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,385 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 2,000 shares of common stock and 645 shares of common stock acquired by the Reporting Person on April 30, 2020 and October 30, 2020 respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; (b) 3,637 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 11,000 shares subject to such RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; F3 · balance_after: (c) 3,833 shares subject to the Reporting Person's April 25, 2019 grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; and (d) 3,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in three annual installments of 1,000 shares on each of March 25, 2021, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended Read SEC document |
| February 25, 2021 Filed Apr 28, 2021 00:45 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-028741 · doc4a.xml · derivative · entry 3 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2031-02-24 F6 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Apr 28, 2021 00:45 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028741 · doc4a.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,135 F4 · shares: Represents 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. F5 · shares: This Form 4/A is being filed solely to correct the stated amount included in Footnote 4 on the Form 4 filed on behalf of the Reporting Person on March 1, 2021 to be 13,750 shares subject to RSUs vesting which was erroneously reported to be 44,000 shares in such Footnote 4. F2 · balance_after: Includes: (a) 2,000 shares of common stock and 645 shares of common stock acquired by the Reporting Person on April 30, 2020 and October 30, 2020 respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; (b) 3,637 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 11,000 shares subject to such RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; F3 · balance_after: (c) 3,833 shares subject to the Reporting Person's April 25, 2019 grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; and (d) 3,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in three annual installments of 1,000 shares on each of March 25, 2021, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended Read SEC document |
| February 25, 2021 Filed Apr 28, 2021 00:45 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,863 | $11.19 | $20,846.97 |
DisclosureSEC source: 0001209191-21-028741 · doc4a.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,385 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 2,000 shares of common stock and 645 shares of common stock acquired by the Reporting Person on April 30, 2020 and October 30, 2020 respectively under the Issuer's 2010 Employee Stock Purchase Plan, as amended; (b) 3,637 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 11,000 shares subject to such RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; F3 · balance_after: (c) 3,833 shares subject to the Reporting Person's April 25, 2019 grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; and (d) 3,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in three annual installments of 1,000 shares on each of March 25, 2021, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended Read SEC document |
| April 25, 2020 Filed Apr 28, 2020 22:59 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 647 | $8.32 | $5,383.04 |
DisclosureSEC source: 0001209191-20-026045 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,603 F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on April 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 24, 2020 of $8.32/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes: 1,270 shares resulting from the April 25, 2020 vesting of Reporting Person's April 25, 2019 restricted stock unit ("RSU") grant; 3,833 shares subject to such RSU grant that will vest in two remaining annual installments on April 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 16,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020; and 3,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on March 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 23:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021346 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,250 F1 · shares: Represents 3,000 shares subject to restricted stock units granted on March 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. F2 · balance_after: Includes 5,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on April 25, 2019 and 16,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:50 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 33,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013239 · doc4a.xml · derivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2030-02-02 F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:50 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013239 · doc4a.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,250 F1 · shares: Represents 16,500 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:34 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 33,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013233 · doc4.xml · derivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2030-02-02 F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:34 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013233 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,250 F1 · shares: Represents 16,500 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.